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Equine grass sickness (EGS) is a polyneuropathy with a case
mortality rate of approximately 85%. While epidemiological
studies have identiﬁed numerous risk factors, there is currently
no preventive healthcare measure available for EGS prevention.
Previous research suggests that EGS may represent a toxico-in-
fectious form of botulism involving Clostridium botulinum type C.
Other equine clostridial diseases are successfully prevented by
vaccination, implying that it should be possible to prevent EGS by
vaccination. As EGS cannot be induced experimentally, a ﬁeld trial
represents the only method of evaluating the effect of vaccina-
tion. This pilot study aimed to inform sample size and trial
methodology for a proposed full-scale triple-blinded randomised
placebo-controlled ﬁeld trial of a C. botulinum type C toxoid
vaccine in the prevention of EGS. Healthy client-owned horses/
ponies residing on premises previously affected by a high inci-
dence and frequency of EGS were included. Horses/ponies were
randomly allocated, at premises-level, stratiﬁed by age, to vaccine
or placebo treatment groups at a 1:1 ratio. Baseline and follow-up
premises and horse data were obtained via telephone question-
naires. Participating veterinary surgeons administered the pri-
mary course of vaccine/placebo on days 0, 21, 42, followed by a
booster injection on day 224. Following appropriate training,
owners completed post-treatment daily observations for seven
days following each treatment. Five participating practices
recruited 10 EGS-affected premises in Scotland, with a median
baseline incidence of 2.2 EGS cases per 100 horse-years-at-risk.
109 horses/ponies were enrolled: 13 were withdrawn prior to
randomisation, and 1 was excluded following randomisation
(Figure 1). Median age at enrolment was 6 years. Age (p¼0.34),
gender (p¼0.15) and breed (p¼0.94) distributions did not differ
between treatment groups. 95 horses/ponies completed the
primary treatment course, and 87 horses/ponies received
booster injections, representing a retention rate of 90.5%. No
signiﬁcant adverse events were reported and incidence of
owner-reported injection site abnormalities was 0.05 per horse-
week-at-risk, none of which required treatment. One histologi-
cally-conﬁrmed EGS case occurred during the study, represent-
ing an incidence of 1.25 cases per 100 horse-years-at-risk. There
was no difference in the risk of EGS between treatment groupsFigure 1. Enrolment and treatment group allocation in a pilot ﬁeld trial of
Clostridium botulinum type C vaccination for EGS prevention.(p¼0.62). Serological analyses demonstrated a signiﬁcant increase
in C. botulinum type C antibody titres following the primary
treatment course in vaccinated horses/ponies compared to the
placebo group (p<0.001), indicating seroconversion following
primary vaccination. This study provided evidence of vaccine
safety under conditions of ﬁeld use, serological evidence of im-
mune response to vaccination and informed modiﬁcations to trial
methodology for a subsequent nationwide ﬁeld trial. This study
was funded by Neogen Corporation and the Animal Health Trust.
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Knowledge of the anchor motifs of equineMajor Histocompatibility
Complex (MHC) class I molecules and identiﬁcation of the path-
ogen-derived peptides that bind to them is critical for the design of
vaccines that can stimulate effective T-cell mediated immunity to
prevent diseases caused by Equine Inﬂuenza Virus, Equine
Herpesvirus, and other microorganisms. Recently we determined
the peptide binding motif of the Equine Leukocyte Antigen ELA-
A3.1 classical MHC class I molecule using a standard immuno-
chemical approach (Bergmann et al., 2015). Endogenously bound
peptides were eluted from P-815 cells transfected with the ELA-
A3.1 gene using an equine speciﬁc monoclonal antibody. The pep-
tides were sequenced using tandem mass spectrometry and
revealed a nonamer with anchoring amino acids at positions 2
(aspartic acid) and 9 (isoleucine or leucine). Using an independent
method horse MHC class I expressionwas stabilized in RMA-S cells
transfected with ELA-A3.1 by screening with a library of 15-mer
peptides that overlapped by 10 amino acids and spanned the entire
Immediate Early (IE) protein of Equine Herpesvirus type 1 (EHV-1).
One of the IE-derived peptides (PPARDGARFGELAAS) stabilized the
ELA-A3.1 MHC class I molecule. This was conﬁrmed and the
sequence further narrowed by testing with shorter peptides. The
promiscuously binding nonamer SDYLELDTI also stabilized ELA-
A3.1 expression. Taken together, these results point to the EHV-1 IE-
derived peptide RDGARFGEL as a candidate for studies of cytotoxic
T-cell immunity to EHV-1 in the horse. Other in vivo studies have
shown that the IE protein contains immunogenic peptides that can
induce protective immunity against this important viral pathogen.
These results pave the way for development of assays for antigen-
speciﬁc equine T-cells that can be used in studies of viral immunity
or to assess the efﬁcacy of vaccines.
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